ÂÜÀòÂÒÂ×

Amir Lahav is a prominent leader in the health technology sector, currently serving as Founder and CEO of SkyMedAI since January 2024. As an External Advisory Board Member of the B2AI-Voice Consortium, Amir contributes to the ethical development of artificial intelligence voice biomarkers. Additionally, Amir holds positions as Advisory Board Member and Investor at Lapsi Health, and Advisory Board Member for Modality.AI, Blue Spark Technologies, and Videra Health. Amir also serves as a Strategic Business Advisor for Mitsubishi Tanabe Pharma America, focusing on digital healthcare innovations. Previously, Amir has acted as a Strategic Advisor for Redenlab, enhancing their clinical portfolio and global strategy on speech biomarkers. Educational credentials include a Postdoctoral Fellowship in Neurology from Harvard Medical School and a Doctor of Science from Boston University in Health and Rehabilitation Sciences.